Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Celgene Corporation : to Announce Third Quarter 2017 Results

share with twitter share with LinkedIn share with facebook
share via e-mail
10/04/2017 | 10:25am CET

Release date- 03102017 -

SUMMIT, N.J. - Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Thursday, October 26, 2017 at 9 a.m. ET to discuss third quarter 2017 financial and operational results.

The webcast can be accessed from the Investor Relations page at www.celgene.com.

Celgene will also host a webcast of an investor event at the MSParis2017-7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) - American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Meeting on Saturday, October 28 at 6:00 p.m. CEST (12:00 p.m. ET). Members of Celgene's management team and clinical investigators will discuss the data presentations at the ECTRIMS Meeting. The event will be webcast live and will be available in the Investor Relations section of the Company's web site at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Forward Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'plans,' 'will,' 'outlook' and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.


Tel: 908-673-9969

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
02:56p CELGENE CORPORATION : and bluebird bio Announce Updated Results from Ongoing Mul..
02:56p ACCELERON PHARMA : Announces Updated Results from Ongoing Phase 2 Trials of Lusp..
11:38a BEIGENE : falls on immune events for B cell cancer combo
11:37a BLUEBIRD BIO : proposes $600M follow-on after ASH gains
11:28a CELGENE : Here Are Two Big Movers From The American Society Of Hematology (ASH) ..
09:19a BLUEBIRD BIO : Stock Soars on Unprecedented Blood Cancer Study Results
12/11 CELGENE : Juno Therapeutics and Celgene Corporation Release Additional Data from..
12/11 CELGENE : Juno Therapeutics and Celgene Corporation Release Additional Data from..
12/08 NASDAQ 100 MOVERS : Viab, alxn
12/08 S&P 500 MOVERS : Coo, alxn
More news
News from SeekingAlpha
09:35a CUTTING EDGE GENE THERAPIES : Beta-Thalassemia Breakthroughs (Part I)
12:19a BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Bluebird Bio's Success, Spark's Hemophili..
12/11 Buy Celgene And Regeneron On The Dips As Insiders Are Buying
12/11 Amgen's Kyprolis extends overall survival in blood cancer patients
12/11 Celgene (CELG) Presents At 59th American Society Of Hematology Annual Meeting..
Financials ($)
Sales 2017 12 966 M
EBIT 2017 7 266 M
Net income 2017 4 051 M
Debt 2017 4 495 M
Yield 2017 -
P/E ratio 2017 21,14
P/E ratio 2018 15,56
EV / Sales 2017 6,90x
EV / Sales 2018 5,72x
Capitalization 85 030 M
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 125 $
Spread / Average Target 16%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.15%218 773
PFIZER9.30%215 837
ROCHE HOLDING LTD.3.40%209 423
MERCK AND COMPANY-6.96%153 659